Skip to main content
Erschienen in: Uro-News 5/2020

11.05.2020 | Antibiotika | Fortbildung

Riskante Fluorchinolone

Zeitgemäße Antibiotikaprophylaxe bei der transrektalen Prostatabiopsie

verfasst von: Prof. Dr. med. Florian Wagenlehner, PD Dr. med. Gernot Bonkat, PD Dr. med. Adrian Pilatz

Erschienen in: Uro-News | Ausgabe 5/2020

Einloggen, um Zugang zu erhalten

Auszug

Präoperative antibiotische Prophylaxe hat sich bei der transrektalen Prostatabiopsie als sinnvoll erwiesen. Die dafür häufig eingesetzten Fluorchinolone bergen jedoch das Risiko schwerer Nebenwirkungen. Deswegen ist es unerlässlich, die Therapiealternativen zu kennen. …
Literatur
1.
Zurück zum Zitat Wagenlehner FM et al. Infective complications after prostate biopsy: outcome of the Global Prevalence Study of Infections in Urology (GPIU) 2010 and 2011, a prospective multinational multicentre prostate biopsy study. Eur Urol. 2013; 63: 521-7 Wagenlehner FM et al. Infective complications after prostate biopsy: outcome of the Global Prevalence Study of Infections in Urology (GPIU) 2010 and 2011, a prospective multinational multicentre prostate biopsy study. Eur Urol. 2013; 63: 521-7
2.
Zurück zum Zitat Loeb S. Infection after Transrectal Ultrasonography-Guided Prostate Biopsy: Increased Relative Risks after Recent International Travel or Antibiotic Use. BJU Int. 2012; 109: 1785-6 Loeb S. Infection after Transrectal Ultrasonography-Guided Prostate Biopsy: Increased Relative Risks after Recent International Travel or Antibiotic Use. BJU Int. 2012; 109: 1785-6
3.
Zurück zum Zitat Loeb S et al. Complications after prostate biopsy: data from SEER-Medicare. J Urol. 2011; 186: 1830-4 Loeb S et al. Complications after prostate biopsy: data from SEER-Medicare. J Urol. 2011; 186: 1830-4
4.
Zurück zum Zitat Loeb S et al. Infectious complications and hospital admissions after prostate biopsy in a European randomized trial. Eur Urol. 2012; 61: 1110-4 Loeb S et al. Infectious complications and hospital admissions after prostate biopsy in a European randomized trial. Eur Urol. 2012; 61: 1110-4
5.
Zurück zum Zitat Loeb S et al. Systematic review of complications of prostate biopsy. Eur Urol. 2013; 64: 876-92 Loeb S et al. Systematic review of complications of prostate biopsy. Eur Urol. 2013; 64: 876-92
6.
Zurück zum Zitat Nam RK et al. Increasing hospital admission rates for urological complications after transrectal ultrasound guided prostate biopsy. J Urol. 2010; 183: 963-8 Nam RK et al. Increasing hospital admission rates for urological complications after transrectal ultrasound guided prostate biopsy. J Urol. 2010; 183: 963-8
7.
Zurück zum Zitat Nam RK et al. Increasing hospital admission rates for urological complications after transrectal ultrasound guided prostate biopsy. J Urol. 2013; 189(1 Suppl): S12-7 Nam RK et al. Increasing hospital admission rates for urological complications after transrectal ultrasound guided prostate biopsy. J Urol. 2013; 189(1 Suppl): S12-7
8.
Zurück zum Zitat Steensels D et al. Fluoroquinolone-resistant E. coli in intestinal flora of patients undergoing transrectal ultrasound-guided prostate biopsy--should we reassess our practices for antibiotic prophylaxis? Clin Microbiol Infect. 2012;1 8: 575-81 Steensels D et al. Fluoroquinolone-resistant E. coli in intestinal flora of patients undergoing transrectal ultrasound-guided prostate biopsy--should we reassess our practices for antibiotic prophylaxis? Clin Microbiol Infect. 2012;1 8: 575-81
9.
Zurück zum Zitat Halpern JA et al. Indications, Utilization and Complications Following Prostate Biopsy: New York State Analysis. J Urol. 2017; 197: 1020-5 Halpern JA et al. Indications, Utilization and Complications Following Prostate Biopsy: New York State Analysis. J Urol. 2017; 197: 1020-5
10.
Zurück zum Zitat Roberts MJ et al. Prostate Biopsy-related Infection: A Systematic Review of Risk Factors, Prevention Strategies, and Management Approaches. Urology. 2017; 104: 11-21 Roberts MJ et al. Prostate Biopsy-related Infection: A Systematic Review of Risk Factors, Prevention Strategies, and Management Approaches. Urology. 2017; 104: 11-21
11.
Zurück zum Zitat Bonkat G et al. In the Line of Fire: Should Urologists Stop Prescribing Fluoroquinolones as Default? Eur Urol. 2019; 75: 205-7 Bonkat G et al. In the Line of Fire: Should Urologists Stop Prescribing Fluoroquinolones as Default? Eur Urol. 2019; 75: 205-7
12.
Zurück zum Zitat Tandan M et al. Adverse events of fluoroquinolones vs. other antimicrobials prescribed in primary care: A systematic review and meta-analysis of randomized controlled trials. Int J Antimicrob Agents. 2018; 52: 529-40 Tandan M et al. Adverse events of fluoroquinolones vs. other antimicrobials prescribed in primary care: A systematic review and meta-analysis of randomized controlled trials. Int J Antimicrob Agents. 2018; 52: 529-40
13.
Zurück zum Zitat DeLaney MC. Risks associated with the use of fluoroquinolones. Br J Hosp Med (Lond). 2018; 79: 552-5 DeLaney MC. Risks associated with the use of fluoroquinolones. Br J Hosp Med (Lond). 2018; 79: 552-5
14.
Zurück zum Zitat Kabbani S et al. Opportunities to Improve Fluoroquinolone Prescribing in the United States for Adult Ambulatory Care Visits. Clin Infect Dis. 2018; 67: 134-6 Kabbani S et al. Opportunities to Improve Fluoroquinolone Prescribing in the United States for Adult Ambulatory Care Visits. Clin Infect Dis. 2018; 67: 134-6
15.
Zurück zum Zitat Marchant J. When antibiotics turn toxic. Nature. 2018; 555: 431-3 Marchant J. When antibiotics turn toxic. Nature. 2018; 555: 431-3
16.
Zurück zum Zitat BfArM. Fluorchinolone -langanhaltende und beeinträchtigende Nebenwirkungen im Bereich Muskeln, Gelenke und Nervensystem; Umsetzung des Durchführungsbeschlusses der EU-Kommission. 2019 BfArM. Fluorchinolone -langanhaltende und beeinträchtigende Nebenwirkungen im Bereich Muskeln, Gelenke und Nervensystem; Umsetzung des Durchführungsbeschlusses der EU-Kommission. 2019
17.
Zurück zum Zitat EMA. Disabling and potentially permanentside effects lead to suspension or restrictionsof quinolone and fluoroquinolone antibiotics. EMA/795349/2018. EMA. Disabling and potentially permanentside effects lead to suspension or restrictionsof quinolone and fluoroquinolone antibiotics. EMA/795349/2018.
18.
Zurück zum Zitat Bonkat G et al. Time to Adapt Our Practice? The European Commission Has Restricted the Use of Fluoroquinolones since March 2019. Eur Urol. 2019; 76: 273-5 Bonkat G et al. Time to Adapt Our Practice? The European Commission Has Restricted the Use of Fluoroquinolones since March 2019. Eur Urol. 2019; 76: 273-5
19.
Zurück zum Zitat Wagenlehner FM et al. Reducing infection rates after prostate biopsy. Nat Rev Urol. 2014; 11: 80-6 Wagenlehner FM et al. Reducing infection rates after prostate biopsy. Nat Rev Urol. 2014; 11: 80-6
20.
Zurück zum Zitat Pilatz A et al. Antibiotic Prophylaxis for the Prevention of Infectious Complications following Prostate Biopsy: A Systematic Review and Meta-Analysis. J Urol. 2020; https://doi.org/10.1097/JU.0000000000000814 Pilatz A et al. Antibiotic Prophylaxis for the Prevention of Infectious Complications following Prostate Biopsy: A Systematic Review and Meta-Analysis. J Urol. 2020; https://​doi.​org/​10.​1097/​JU.​0000000000000814​
21.
Zurück zum Zitat Roberts MJ et al. Comparison of fosfomycin against fluoroquinolones for transrectal prostate biopsy prophylaxis: an individual patient-data meta-analysis. World J Urol. 2018; 36: 323-30 Roberts MJ et al. Comparison of fosfomycin against fluoroquinolones for transrectal prostate biopsy prophylaxis: an individual patient-data meta-analysis. World J Urol. 2018; 36: 323-30
22.
Zurück zum Zitat Bonkat G et al. EAU Guidelines on urological infections. In: (EAU) EAoU. 2019. 1-60 Bonkat G et al. EAU Guidelines on urological infections. In: (EAU) EAoU. 2019. 1-60
Metadaten
Titel
Riskante Fluorchinolone
Zeitgemäße Antibiotikaprophylaxe bei der transrektalen Prostatabiopsie
verfasst von
Prof. Dr. med. Florian Wagenlehner
PD Dr. med. Gernot Bonkat
PD Dr. med. Adrian Pilatz
Publikationsdatum
11.05.2020
Verlag
Springer Medizin
Schlagwort
Antibiotika
Erschienen in
Uro-News / Ausgabe 5/2020
Print ISSN: 1432-9026
Elektronische ISSN: 2196-5676
DOI
https://doi.org/10.1007/s00092-020-4121-x

Weitere Artikel der Ausgabe 5/2020

Uro-News 5/2020 Zur Ausgabe

Neu im Fachgebiet Urologie

19.04.2024 | EAU 2024 | Kongressbericht | Nachrichten

Ureterstriktur: Innovative OP-Technik bewährt sich

19.04.2024 | EAU 2024 | Kongressbericht | Nachrichten

Prostatakarzinom: EU initiiert neues Screeningkonzept

19.04.2024 | EAU 2024 | Kongressbericht | Nachrichten

Blasenkarzinom – Biomarker statt Zytologie?

Update Urologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.